Benchmark No. 17 Parkinson's disease Management 3rd Edition

British Association of Neuroscience Nurses



Benchmark No. 17

Parkinson's Disease Management 3rd Edition

Copyright © 2024 British Association of Neuroscience Nurses. All rights reserved.

First PDF edition printed 2019 in the United Kingdom. Second PDF edition printed 2024 in the United Kingdom. This PDF third edition printed 2024 in the United Kingdom (available online). A catalogue record for this book is available from the British Library.

ISBN 978-1-911059-30-1

No part of this book shall be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information retrieval system without written permission of the publisher.

Published by the British Association of Neuroscience Nurses

For more copies of this book, please email: info@bann.org.uk

Designed and Set by the British Association of Neuroscience Nurses www.bann.org.uk

Printed in the United Kingdom

Although every precaution has been taken in the preparation of this publication, the publisher and authors assume no responsibility for errors or omissions. Neither is any liability assumed for damages resulting from the use of this information contained.

1



History

The Neuroscience Nursing Benchmarking Group (NNBG) was established in the 1990's as a result of increasing concerns over inconsistencies in practices as part of a subsidiary of BANN. The group aims to improve on the quality of care by comparing and sharing practice with each other, and set explicit standards for comparison of current practice against the ideal standard. The group is committed to searching for the best evidence related to specific areas of neuroscience practice. Membership of the group consists of representatives from neuroscience units within the UK and Ireland, together with educational colleagues from both the NHS/HSC and Higher Educational Institutes. The group is further subdivided into regions and this benchmark was developed by the North East group of the NNBG in 2007.

In 2016, the NNBG consolidated back into BANN and further information about NNBG can be found on the BANN website www.BANN.org.uk.

BANN would like to acknowledge the leadership and significant contribution made by the NNBG, and all its contributors, to neuroscience nursing over the years.

Benchmark No.17

Parkinson's disease Management

Key Points

- Following assessment, a patient centred management plan is implemented to ensure seamless delivery of services and continuity of care.
- Evidence based guidelines/protocols are utilised in the medication management of patients with Parkinson's disease.
- Management of medication for people with Parkinson's disease should be carried out by appropriately trained healthcare professionals.
- The Parkinson's disease specialist team are informed of all new referrals or re-admissions.
- A regular review of medications must be undertaken on an individual patient basis.
- To optimise symptom control, patients must receive their prescribed medication at specific times in accordance with a patient centred management plan.
- Medications should never be withdrawn abruptly and if unable to take oral medications, alternatives must be provided.
- Self-medication should be supported wherever possible.
- Patients must have access to information regarding their medication regime.
- Nursing staff and patients have access to 'Get It On Time' (GIOT) clocks to enable timely medication administration.
- All documentation meets the needs of the individual patient and is based upon the best available evidence.
- There is evidence of daily multi-disciplinary evaluations of care delivered which must be completed in a full and timely manner.
- The care plan is evidence based, dated and reviewed within the last two years and updated accordingly.

Date completed: Jan 2024 Review Date: Jan 2026

FACTOR 1 - Documentation - Assessment and Implementation of care

An individualised plan of care is implemented and evaluated, specific to all aspects of care relating to the patients` individual physical and psychological needs. This must include an assessment of: - a) Mobility/Falls risk b) Saliva c) Pain d) Rowels and Bladder. NICE (2017)		STATEMENT OF BEST PRACTICE	EVIDENCE & REFERENCES	ACHIEVED	NOT ACHIEVED	VARIABLES
e) Bradykinesia/ dyskinesia/rigidity/tremor f) Postural hypotension g) Freezing episodes affecting speech, swallowing, facial expressions. h) Formal assessment of swallowing – signs (pre-existing dysphagia, poor appetite) or symptoms (aspiration pneumonia, weight changes). i) 'On/Off fluctuations in condition (e.g., if 'off cannot take medications) j) Assessment of sleep disturbances due to PD related motor symptoms, treatment-related disorders, psychiatric symptoms or rapid eye movement behavioural disorders k) Cognitive impairment - confusion, hallucinations, paranoia, history of delirium. l) Hypersexuality (linked to medications) m) Dopamine Dysregulation Syndrome (DDS), impulse control disorders n) Punding behaviours (obsessive habits) o) Psychological aspects e.g., depression and anxiety p) Risks associated with other treatment regimes. q) 'End of life' concerns	1.0	aspects of care relating to the patients' individual physical and psychological needs. This must include an assessment of: - a) Mobility/Falls risk b) Saliva c) Pain d) Bowels and Bladder e) Bradykinesia/ dyskinesia/rigidity/tremor f) Postural hypotension g) Freezing episodes affecting speech, swallowing, facial expressions. h) Formal assessment of swallowing – signs (pre-existing dysphagia, poor appetite) or symptoms (aspiration pneumonia, weight changes). i) 'On/Off' fluctuations in condition (e.g., if 'off' cannot take medications) j) Assessment of sleep disturbances due to PD related motor symptoms, treatment-related disorders, psychiatric symptoms or rapid eye movement behavioural disorders k) Cognitive impairment - confusion, hallucinations, paranoia, history of delirium. l) Hypersexuality (linked to medications) m) Dopamine Dysregulation Syndrome (DDS), impulse control disorders n) Punding behaviours (obsessive habits) o) Psychological aspects e.g., depression and anxiety p) Risks associated with other treatment regimes.	Parkinson's UK (parkinsons.org.uk) NICE (2017) NHS (2018)			

Benchmark Number: 17 Parkinson's Disease Management

Date completed: Jan 2024 Review Date: Jan 2026

FACTOR 2 - Protocol

	STATEMENT OF BEST PRACTICE	EVIDENCE & REFERENCES	ACHIEVED	NOT ACHIEVED	VARIABLES
2.0	An initial assessment of the effectiveness of current medication is evident (includes patient self-assessment diaries).	NICE (2017)			
2.1	A recognised assessment tool is available which includes guidance on: - a) The use of on/off charts b) Timing of medications c) Monitoring response or adverse reactions to medication regimes	NICE (2017)			
2.2	Parkinson's medications are prescribed and administered in accordance with the patients' personalised regime (including drug administration via Duopa pump)	RCN (2020)			
2.3	Continuous assessment of the patient's mental capacity to self-medicate is undertaken and documented. - Where a patient is deemed to be competent, self-medication should be the preferred option in accordance with National guidance.	DH (2005)			
2.4	There is documented evidence of the patient's medication management plan which is discussed with the patient. This should include: - a) Documented choice of drug(s), route, and timings b) Prescribe generic named medications rather than branded medications.	Learning Hub Parkinson's UK (parkinsons.org.uk) NICE (2017)			
2.5	Adjustment of medication is only undertaken following collaboration between the in Parkinson disease specialist and pharmacist.				

Benchmark Number: 17 Parkinson's Disease Management

Date completed: Jan 2024 Review Date: Jan 2026

FACTOR 3 – Education

	STATEMENT OF BEST PRACTICE	EVIDENCE & REFERENCES	ACHIEVED	NOT ACHIEVED	VARIABLES
3.0	Documentation is completed which includes:				
	 a) Medication charts - the patients' medication regime including timings. b) Patient self-assessment of personal medication regime is supported (i.e., encourage completion of patient diary). 	NMC (2018)			
	 c) Subcutaneous medication – regular evaluations of the injection site for signs of irritation, and changes to alternative subcutaneous sites. d) Duopa pump – monitoring of PEG-J tube entry site, titration of dosage 	NICE (2017)			
	to effectively control symptoms. e) Practitioner assessment of medication effectiveness and adverse effects i.e., on/off chart. f) Measurements of lying and standing blood pressure is performed (postural hypotension is more prevalent due to the autonomic response).	Learning Hub Parkinson's UK (parkinsons.org.uk)			
3.1	All documentation supports the patient-centred decision-making process and their on-going management	Warren <i>et al</i> , (2016)			
3.2	In accordance with specific medication regimes, baseline clinical investigations are completed and repeated as clinically indicated (e.g. liver function, ECG, bone density measurement)	NICE (2017)			

Benchmark Number: 17 Parkinson's Disease Management

Date completed: Jan 2024 Review Date: Jan 2026

FACTOR 4 – Patient Information

	STATEMENT OF BEST PRACTICE	EVIDENCE & REFERENCES	ACHIEVED	NOT ACHIEVED	VARIABLES
4.0	Patient/family/carers are given the following information, which should be discussed with their specialist team and clearly documented: - a) Contact details of the P.D Specialist nurse b) The reason for their current admission c) Information relating to their medication including expected efficacy/effects of the medication regimes. d) Education on early signs and symptoms of potential adverse effects of medication e) Advice related to maintaining posture and balance activity. f) Entitlements to care assistance and local support services.	Parkinson's UK 2017, 2018 NICE 2017, Balconi et al, 2018 RCP, 2020 Learning Hub Parkinson's UK (parkinsons.org.uk)			
4.1	To enable continuity of care with Community services and the seamless delivery of care, patients, carers and family are given the following discharge information that includes: - a) Written detailed information of any follow up(s) b) Supporting documentation to manage their symptoms and medication i.e., symptom diary and a clearly documented medication regime. c) Contact details for supplies of medication and equipment d) Signposting to additional information resources	DH 2005			

References

Legislation.gov.uk (2000) Adults with Incapacity (Scotland) Act (2000) Available from: https://www.legislation.gov.uk/asp/2000/4/contents Date Last accessed: 28/06/2024

Balconi M, Angioletti L, Siri C, Meucci N, Pezzoli G. (2018) Gambling behavior in Parkinson's Disease: Impulsivity, reward mechanism and cortical brain oscillations. *Psychiatry Res*earch 270:974–80

Cotterell P. (2018) Parkinson's disease: symptoms, treatment options and nursing care. *Nursing Standard*. 33(7):53-58.

Department of Health (2005) *National Service Framework for Long-term Conditions*. Available from: https://www.gov.uk/government/publications/quality-standards-for-supporting-people-with-long-term-conditions Date last accessed: 28/06/2024

Legislation.gov.uk (2005) *Mental Capacity Act (2005)*. Available from:

https://www.legislation.gov.uk/ukpga/2005/9/contents Date Last accessed: 28/06/2024

Parkinson's UK (2024) *Learning Hub.* Available from:

https://www.parkinsons.org.uk/professionals/learning-hub Date last accessed: 28/06/2024

Legislation.gov.uk (2024) Mental Health Act Scotland (2015) Available from: https://www.legislation.gov.uk/asp/2015/9/contents Date Last accessed: 28/06/2024

Parkinson's UK NICE guideline (NG71) (2017) Parkinson's disease in Adults Available from: https://www.parkinsons.org.uk/professionals/resources/nice-guideline-ng71-parkinsons-disease-adults Date Last accessed: 28/06/2024

NHS England (2018) NHS Right Care scenarios: Sarah's Story: Parkinson's. Available from: https://www.england.nhs.uk/rightcare/scenarios/ Date Last accessed: 28/06/2024

NMC (2018) Standards of proficiency for registered nurses. London: Nursing and Midwifery Council.

Skelly, R (2020) Gambling addiction and Parkinson's disease – supporting better patient care (blog). Available from: https://www.rcp.ac.uk/news-and-media/news-and-opinion/gambling-addiction-and-parkinson-s-disease-supporting-better-patient-care/ Date Last accessed: 28/06/2024

RCN (2020) Medicines management: an overview for nursing. Available from: https://www.rcn.org.uk/clinical-topics/medicines-management/professional-resources Date Last accessed: 28/06/2024

Wijdicks, E.F (2022) Neuroleptic malignant syndrome. Available from: https://www.uptodate.com/contents/neuroleptic-malignant-syndrome#references Date last accessed: 28/06/2024

Warren, E. Eccles, F. Travers, V. Simpson, J. (2016) The experience of being diagnosed with Parkinson's disease. *British Journal of Neuroscience Nursing*. 12 (6): 265-309





Benchmark No. 17 (3rd edition)
Parkinson's Disease Management



